Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 55OTHER_GOV 7INDUSTRY 4NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Multiple Myeloma 1Hemangioma, Capillary 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Propranolol × Clear all
NCT06120140 2026-05-08

COCOON

Janssen Research & Development, LLC

Phase 2 Active not recruiting
305 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05561751 2026-02-12

Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

GPCR Therapeutics, Inc.

Phase 2 Completed
30 enrolled
Plasma cell

Multiple Myeloma

NCT01857817 2018-04-26

Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer

Vicus Therapeutics

Phase 2 Terminated
35 enrolled
Genitourinary

Prostatic Neoplasms

NCT01056341 2015-12-10

Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy

Pierre Fabre Dermatology

Phase 2/3 Completed
512 enrolled 13 charts

Hemangioma, Capillary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡